Ron Bentsur - 30 Jun 2026 Form 4 Insider Report for Nuvectis Pharma, Inc. (NVCT)

Reporting relationship: Chairman & CEO, Director, 10%+ Owner
Issuer ticker: NVCT
Reported as of: 30 Jun 2026
Net transaction value: +$250,000
SEC form: 4
Accepted by SEC: 01 Jul 2026, 13:39:50 UTC
Prior SEC filing: 09 Jan 2026
Source filing: View source filing
Reporting owner signature: /s/ Ron Bentsur

Key filing fact

Ron Bentsur filed Form 4 for Nuvectis Pharma, Inc. (NVCT) on 01 Jul 2026.

Key facts

This page summarizes Ron Bentsur's Form 4 filing for Nuvectis Pharma, Inc. (NVCT).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 01 Jul 2026, 13:39.

Change

Previous filing in this sequence was filed on 09 Jan 2026.
Current net transaction value: +$250,000.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001251213 Primary reporting owner

BENTSUR RON

Relationship: Chairman & CEO, Director, 10%+ Owner
Address: C/O NUVECTIS PHARMA, INC., 1 BRIDGE PLAZA, SUITE 275, FORT LEE
Signature: /s/ Ron Bentsur
Signature date: 01 Jul 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

NVCT transaction

Common Stock

Purchase

Transaction value: $250,000
Shares: +12,500
Change %: +0.34%
Price: $20.00
Shares after: 3,688,424
Date: 30 Jun 2026
Ownership: Direct
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

Mr. Bentsur purchased 12,500 shares for $250,000 in the public offering announced on June 29, 2026.

Footnote F2

Includes shares of restricted common stock.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. to update or revoke optional consent for future visits. For more information, see our Privacy Policy .